Renal Cell Carcinoma : Molecular Targets and Clinical Applications / / edited by Ronald M. Bukowski, Robert A. Figlin, Robert J. Motzer

• Pubblicazione: New York, NY : , : Springer New York : , : Imprint : Springer, , 2015
• Edizione: 3rd ed. 2015.
• Descrizione fisica: 1 online resource (620 p.)
• Disciplina: 610; 616.07548; 616994
• Soggetto topico: Oncology ; Nuclear medicine; Oncology; Nuclear Medicine
• Persona (resp. second.): BukowskiRonald M; FiglinRobert A; MotzerRobert J
• Note generali: Description based upon print version of record.
• Nota di bibliografia: Includes bibliographical references and index.
• Nota di contenuto: 1st Edition Preface; 2nd Edition Preface; Histology; von Hippel-Lindau (VHL) Syndrome; Systemic Therapy: Metastatic Disease; References; Contents; Contributors; Chapter 1: Targeted Therapy for Metastatic Renal Cell Carcinoma: Introduction; Background; Molecular Genetics: RCC; Prognostic Factors in Renal Cell Carcinoma; Management of Patients with Advanced RCC; Bevacizumab; Sorafenib; Sunitinib; Pazopanib; Axitinib; mTOR Inhibitors: Temsirolimus; Everolimus; The Evolving Treatment Landscape for RCC; Comparative Clinical Trials; Combination Approaches; Sequential Therapy RCC; Future Approaches ; SummaryReferences; Chapter 2: Renal Cell Carcinoma: Pathologic and Molecular Assessment of Targets; Evolution of the Classification of Renal Cell Carcinomas; Initial Histological Classifications; Chromosomal Findings in Familial Renal Cell Carcinomas: Impact on the Pathology and Therapy of Sporadic Cases; Molecular Pathways in Renal Cell Carcinomas; Pseudo-hypoxic Pathways in Renal Cell Carcinoma; VHL Pathway; Krebs Cycle and Pseudo-hypoxic Pathway; mTOR Pathway; TSC1/TSC2 Pathway; c-MET Pathway in Renal Cell Carcinoma; FLCN Pathway in Renal Cell Carcinoma ; Renal Cell Carcinoma Pathology According to Molecular PathwayPseudo-hypoxic Pathway; Association with VHL Gene Changes and TSC1/TSC2 Loss; Association with Krebs Cycle Mutations; c-MET Pathway; FLCN Pathway; Undefined Pathway; Other Pathological Renal Cell Carcinomas Entities; Unclassified Renal Cell Carcinoma; Conclusions; References; Chapter 3: Genomic Assessment of Renal Cancer; Introduction; Methods for Genomic Characterization; Cytogenetics and Copy Number Change; DNA Sequence and Somatic Mutations; Epigenetic Analysis; Transcript Analysis; Technique Summary ; Cytogenetics and Copy Number Changes in Renal CancerCopy Number Changes in ccRCC; Prognostic Associations with Copy Number Changes in ccRCC; Familial Renal Cancer Due to Chromosome 3 Translocations; Somatic Genetics of Renal Cancer; Mutated Genes in ccRCC; Activation of the PI3K/AKT Signaling Pathway in ccRCC; ccRCC Tumorigenesis and Prognosis in Relation to Genetic Mutation; Epigenetic Regulation in ccRCC; Mutations in Epigenetic Regulatory Genes; PBRM1; BAP1; Histone-Modifying Genes (HMGs); Genomic Assessments of Chromatin; DNA Methylation Phenotypes; Renal Cancer Transcript Assessments ; Non-clear Cell DiseaseConclusions; References; Chapter 4: VHL and HIF in Clear Cell Renal Cell Carcinoma: Molecular Abnormalities and Potential Clinical Applications; Introduction; VHL Gene and Protein; pVHL Structure; pVHL and Hypoxia-Inducible Factors; The HIF Transcription Factors; HIF2α Is More Oncogenic than HIF1α; HIF1α Is a Renal Tumour Suppressor Gene; Differences Between HIF1α and HIF2α; HIF-Independent Functions of pVHL (Table 4.2); VHL and Regulation of the Extracellular Matrix; Microtubule Stabilisation and Maintenance of the Primary Cilium; Regulation of Apoptosis ; Control of Cell Senescence
• Sommario/riassunto: The third edition of this critically acclaimed book has updated and expanded the survey of clinical, biological and pathological management of localized and advanced renal cell carcinoma. Internationally renowned editors and contributors explore the latest developments in molecular genetics, focusing on the novel targets that have been discovered in epithelial renal tumors. Comprehensive and authoritative, Renal Cell Carcinoma: Molecular Targets and Clinical Applications, Third Edition is the definitive text on the rapidly evolving landscape of experimental therapeutics, written and edited by leaders of the field.
• Titolo autorizzato: Renal Cell Carcinoma
• ISBN: 1-4939-1622-X
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Lingua di pubblicazione: Inglese
• Record Nr.: 9910300202303321
• Lo trovi qui: Univ. Federico II